Necrosis- or DNA targeted IL-12 Development Service
Creative Biolabs offers a comprehensive, integrated development pathway designed to convert your interleukin-12 (IL-12) concept into a safe, clinically relevant therapeutic candidate. Our expertise centers on engineering the next generation of IL-12 immunocytokines—fusion proteins that leverage an antibody targeting necrosis-associated antigens (exposed DNA and histones) to deliver a high payload of IL-12 directly to the solid tumor mass. This approach is essential for achieving a local concentration high enough to drive robust CD8+ T-cell and NK cell activation while maintaining systemic tolerability. Our specific deliverables focus on validating the critical safety and efficacy milestones necessary for IND-enabling studies.
Background What We Can Offer Workflow Why Choose Us FAQs Customer Review Related Services Contact Us
The Problem: Systemic Toxicity and the Narrow Therapeutic Index
IL-12 is a potent pro-inflammatory cytokine that orchestrates robust anti-tumor immunity by driving Th1 responses and IFN-γ production. However, first-generation recombinant IL-12 (rIL-12) was severely hampered by a narrow therapeutic window and dose-limiting systemic toxicity, primarily due to excessive systemic IFN-γ and TNFα release. This toxicity prevented achieving therapeutic concentrations in the tumor. The unpredictable nature was evidenced by intravenous (IV) delivery (~40% response rate), yielding significantly higher efficacy than subcutaneous (SC) delivery (~7% response rate), underscoring the failure of non-localized rIL-12 pharmacokinetics.
Specific Deliverables and Solutions Customers Can Expect
Safety De-Risking
Quantitative proof that the targeted construct induces significantly lower serum IFN-γ release compared to non-targeted recombinant rIL-12 in preclinical models, validating the critically improved therapeutic index.
Enhanced PK Profile
Confirmation of a longer plasma half-life and superior tumor-to-tissue ratio via in vivo imaging and pharmacokinetics (PK) analysis, ensuring sustained tumor exposure.
Durable Anti-Tumor Efficacy
Data demonstrating the construct's ability to drive robust CD8+ T-cell infiltration, generate antigen-specific cytotoxic T lymphocyte (CTL) responses, and establish long-lasting immune memory against tumor rechallenge.
Discover How We Can Help - Request a Consultation Today to Discuss Your Project's Specific Timeline and Scope!
Workflow: Designing and Validating Targeted IL-12 Immunocytokines
Our structured and transparent workflow ensures every stage of the immunocytokine development is optimized for clarity, professional standards, and clear decision points for potential clients.
Why Choose Us?
Creative Biolabs' targeted IL-12 platform is engineered for a wide therapeutic window, built on solving early clinical failures. Our primary differentiator is validated safety control, with IgG1 fusion demonstrating significant attenuation of the systemic toxicity driver, IFN-γ. The IgG1 fusion is engineered for tumor microenvironment (TME) penetration, using a long half-life to maximize binding to exposed DNA/histones in necrotic cores for high local drug concentrations. This mechanism offers proven synergistic efficacy with chemo/radiation and consistently drives the induction of durable memory and strong, antigen-specific CTL responses.
Experience the Creative Biolabs advantage - Get a quote today to start leveraging our platform expertise for your project.
FAQs
Q: Can this targeted IL-12 still be combined with immune checkpoint inhibitors (ICIs) if it targets necrosis?
A: Absolutely. The necrosis-targeting mechanism is complementary to ICI activity. IL-12 acts as an 'immune primer', generating the T cells necessary for ICIs to function effectively.
Q: What specific data is used to validate the improved safety profile of the immunocytokine?
A: The core safety validation relies on comparative PK/PD studies in non-human primates and murine models. Data consistently show the targeted construct induces significantly lower systemic IFN-γ release, providing the quantifiable evidence needed for the wider therapeutic index.
Q: Does the DNA-targeting antibody component interfere with the IL-12's ability to bind its receptor?
A: No. The IL-12 heterodimers are typically fused to the C-terminus of the antibody heavy chains. This design ensures that the IL-12 receptor binding pocket remains fully accessible for T-cell activation while the antibody retains full affinity for the exposed DNA.
Customer Review
-
Exceptional Safety-Efficacy Balance
The attenuation of serum IFN-γ release was profound, allowing us to safely administer doses that achieved tumor regression, a major advantage over traditional rIL-12. - Dr. Har*per
-
Superior Combination Synergy
The construct's ability to target necrosis proved fundamentally synergistic. We observed enhanced immunocytokine accumulation in tumors following radiation, which translated directly into superior anti-tumor effects compared to monotherapy. - Prof. Adam*son
Related Services
To ensure the success of your IL-12 therapeutic strategy, Creative Biolabs offers several complementary services that can be integrated with our necrosis-targeted IL-12 development service:
Cytokine Measurement
Creative Biolabs offers cytokine measurement services (ELISA/multiplex) to study the gut-brain axis. We analyze cytokine levels to reveal links between gut dysbiosis and inflammatory neurological disorders like ASDs.
Learn More →
Tumor Necrosis Factor (TNF) Production Measurement Service
Creative Biolabs measures TNF production using ELISA (traditional/plate array for 32 cytokines), flow cytometry, western blot, and biological assays for functional analysis.
Learn More →
How to Contact Creative Biolabs
The necrosis- or DNA-targeted IL-12 development service from Creative Biolabs is your strategic solution for overcoming the systemic toxicity and PK challenges that have historically impeded this powerful cytokine. By engineering an advanced immunocytokine that accumulates selectively at the tumor site, we provide a validated candidate with a critically improved therapeutic index, superior anti-tumor efficacy, and the ability to generate durable immune memory. Partner with Creative Biolabs to accelerate the delivery of this life-changing therapy to the clinic.
